Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tioga Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Tioga Pharmaceuticals has been formed to develop asimadoline, to treat pain in patients with irritable bowel syndrome and other gastrointestinal diseases. But unlike in-licensers that seek many shots on goal to balance risk, it is singularly focused on development of this asset.

You may also be interested in...



The A-List: 2005's Trend-Shaping Series A Financings

2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.

The A-List: 2005's Trend-Shaping Series A Financings

2005's top early stage venture financings reflect a drive for size and experience on the biotech side, and the demand for less-invasive procedures in the device world. Start-Up lists the top ten Series A rounds of 2005.

Signs of Movement in IBS Drug Development

Despite Big Pharma's struggles, the availability of compounds developed for other pain indications could energize start-ups' interest in irritable bowel syndrome.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091149

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel